Remedy, a developer of low-dose and ultra-compact X-ray solutions, made its debut on the KOSDAQ market on July 13, marking a milestone in the company's growth across medical imaging and industrial non-destructive testing (NDT).
Founded in 2012, Remedy has developed and commercialized portable medical X-ray systems, industrial NDT equipment, and core X-ray components based on its proprietary low-dose, miniaturized, and high-definition X-ray technologies. The company has established an in-house technology platform covering the development of X-ray generators through to finished products, enabling it to serve medical, industrial, and special-purpose applications.
The company's core strength lies in its platform technology that combines low-dose performance, compact design, and high-definition imaging. Remedy stated that it has secured 10 core technologies that support a broad product portfolio, including medical X-ray systems, industrial non-destructive testing equipment, X-ray tubes, emitters, and high-voltage generators.
Among its flagship products is the portable X-ray system Remex-KA6, a lightweight device weighing approximately 2.4 kg. Designed for use in hospitals, emergency rooms, operating theatres, intensive care units, ambulances, emergency helicopters, military facilities, disaster response operations, and mobile clinics, the system delivers high-quality imaging through a 0.4 mm fine-focus design while reducing radiation exposure for both patients and medical personnel using low-dose technology.
The company's public offering attracted strong investor interest. During the public subscription conducted over two days, Remedy recorded a subscription rate of 1,707 to 1, with more than 51.2 million shares subscribed for the 300,000 shares allocated to general investors. The total subscription deposit reached 5.3 trillion won.
Earlier, the institutional demand forecast conducted between June 17 and June 23 drew participation from 2,246 institutions and recorded a competition ratio of 1,146 to 1. The final offering price was fixed at 20,700 won, the upper end of the proposed price band.
The capital raised through the listing will be used to expand production capacity, accelerate research and development activities, strengthen global certifications, and expand the company's international sales network.
“I thank the investors for recognizing the value of our core low-dose, miniaturized X-ray technology,” said Jo Bong-ho, CEO of Remedy, “We will invest the funds secured through the listing into developing next-generation products and expanding production capacity to grow into a global X-ray platform company encompassing industrial non-destructive testing beyond the medical sector.”
Reference: https://www.edaily.co.kr/News/Read?newsId=02082806645514192
